Abstract Search

ey0020.2-11 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.11. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

A Juul , P Backeljauw , M Hojby , M Kawai , RJ Kildemoes , A Linglart , N Zuckerman-Levin , R Horikawa

Brief summary: This is the first multi-national phase 2 dose finding trial aimed at investigating efficacy and safety of the long acting GH (Somapacitan) with daily GH in short children born SGA. 62 GH treatment-naïve short children born SGA were enrolled in the study. Efficacy was valuated with estimated mean annualized height velocity (HV) after 26 weeks of follow-up. Somapacitan showed similar efficacy of daily rhGH. The study will be extended for further 4 years in or...

1 shares

ey0016.10-15 | (1) | ESPEYB16

10.15. Increased prevalence of disordered eating in the dual diagnosis of type 1 diabetes mellitus and celiac disease

I Tokatly Latzer , M Rachmiel , N Zuckerman Levin , K Mazor-Aronovitch , Z Landau , RF Ben-David , C GrafBar-El , N Gruber , N Levek , B Weiss , D Stein , L Lerner-Geva , O Pinhas-Hamiel

To read the full abstract: Pediatr Diabetes. 2018;19:749755.Disordered eating behaviors (DEBs) may lead to full blown eating disorders and these might impair patients adherence to chronic disease management. Both type 1 diabetes mellitus (T1DM) and celiac disease (CD) are associated with DEBs. Adolescents with T1D and eating disorders have worse metabolic control and a higher...

0 shares

ESPE Yearbook of Paediatric Endocrinology

2.11. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study

10.15. Increased prevalence of disordered eating in the dual diagnosis of type 1 diabetes mellitus and celiac disease

BiosciAbstracts